TY - JOUR
T1 - Efficacy of mesenchymal stem cell-delivery using perpendicular multi-needle injections to the skin
T2 - Evaluation of post-ejection cellular health and dermal delivery
AU - Rangatchew, Filip
AU - Rasmussen, Bo Sonnich
AU - Svalgaard, Jesper Dyrendom
AU - Haastrup, Eva
AU - Talman, Maj Lis M.
AU - Bonde, Christian
AU - Fischer-Nielsen, Anne
AU - Drzewiecki, Krzysztof T.
AU - Holmgaard, Rikke
AU - Munthe-Fog, Lea
N1 - Publisher Copyright:
© 2022
PY - 2023
Y1 - 2023
N2 - Aim: Mesenchymal stem cell (MSC)-therapy is increasingly being evaluated in clinical trials. Dermal delivery is not only time consuming but also unreliable, potentially hampering the therapeutic result. Therefore, qualification of cell delivery protocols is essential. This study evaluated a clinically relevant automated multi-needle injection method for cutaneous MSC-therapy, allowing the skin to be readily and timely treated, by assessing both the cellular health post-ejection and dermal delivery. Methods: Following dispensation through the injector (31 G needles: 9- or 5-pin) the cellular health and potency (perceived- and long-term (12 h) viability, recovery, metabolism, adherence, proliferation and IDO1-expression) of adipose-derived stem cells (10–20–50 ×106 cells/ml) were assessed in vitro in addition to dermal delivery of solution in human skin. Results: No significant detrimental effect on the perceived cell viability, recovery, metabolism, adherence or IDO1-expression of either cell concentration was observed. However, the overall long-term viability and proliferation decreased significantly regardless of cell concentration, nonetheless marginally. An injection depth above 1.0 mm resulted in all needles piercing the skin with dermal delivery from up to 89% needles and minimal reflux to the skin surface, and the results were confirmed by ultrasound and histology. Conclusion: The automated injector is capable of delivering dermal cell-doses with an acceptable cell quality.
AB - Aim: Mesenchymal stem cell (MSC)-therapy is increasingly being evaluated in clinical trials. Dermal delivery is not only time consuming but also unreliable, potentially hampering the therapeutic result. Therefore, qualification of cell delivery protocols is essential. This study evaluated a clinically relevant automated multi-needle injection method for cutaneous MSC-therapy, allowing the skin to be readily and timely treated, by assessing both the cellular health post-ejection and dermal delivery. Methods: Following dispensation through the injector (31 G needles: 9- or 5-pin) the cellular health and potency (perceived- and long-term (12 h) viability, recovery, metabolism, adherence, proliferation and IDO1-expression) of adipose-derived stem cells (10–20–50 ×106 cells/ml) were assessed in vitro in addition to dermal delivery of solution in human skin. Results: No significant detrimental effect on the perceived cell viability, recovery, metabolism, adherence or IDO1-expression of either cell concentration was observed. However, the overall long-term viability and proliferation decreased significantly regardless of cell concentration, nonetheless marginally. An injection depth above 1.0 mm resulted in all needles piercing the skin with dermal delivery from up to 89% needles and minimal reflux to the skin surface, and the results were confirmed by ultrasound and histology. Conclusion: The automated injector is capable of delivering dermal cell-doses with an acceptable cell quality.
KW - Cell therapy
KW - Dermal delivery
KW - Injection
KW - Mesenchymal stem cell
KW - Regenerative medicine
KW - Skin therapy
U2 - 10.1016/j.burns.2022.04.020
DO - 10.1016/j.burns.2022.04.020
M3 - Journal article
C2 - 35618513
AN - SCOPUS:85130889744
VL - 49
SP - 633
EP - 645
JO - Burns
JF - Burns
SN - 0305-4179
IS - 3
ER -